PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10676440-6	1999	Previous studies had shown that VIP-treated cultured astrocytes release growth factors including activity-dependent neurotrophic factor (ADNF) and that a 14-amino-acid peptide derived from ADNF protected the developing white matter against ibotenate.	Ibotenic Acid	240-249	vasoactive intestinal polypeptide	Mus musculus	32-35	
9974100-2	1999	In this model, co-treatment with ibotenate and a vasoactive intestinal peptide antagonist (VA) aggravates the excitotoxic lesions, suggesting a protective role of endogenous VIP.	Ibotenic Acid	33-42	vasoactive intestinal polypeptide	Mus musculus	174-177	
9218516-5	1997	The goal of this study was to assess the protective role of VIP against excitotoxic lesions induced by ibotenate in developing mouse brain.	Ibotenic Acid	103-112	vasoactive intestinal polypeptide	Mus musculus	60-63	
9218516-6	1997	VIP cotreatment reduced ibotenate-induced microgyric-like cortical lesions and white matter cysts by up to 77 and 85%, respectively.	Ibotenic Acid	24-33	vasoactive intestinal polypeptide	Mus musculus	0-3	
12106022-5	1990	Furthermore, ibotenate also potentiated the effect of VIP on cAMP formation, while l-homocysteate exhibited an inhibitory action.	Ibotenic Acid	13-22	vasoactive intestinal polypeptide	Mus musculus	54-57	
10027860-5	1999	The goal of the present study was to assess the protective properties of systemically injected VIP analogs against ibotenate-induced excitotoxic white matter lesions in newborn mice.	Ibotenic Acid	115-124	vasoactive intestinal polypeptide	Mus musculus	95-98	
10027860-7	1999	RO-25-1553, a long-lasting cyclic VIP analog, and stearyl-norleucine-VIP, a fatty derivative of VIP, reduced ibotenate-induced white matter cysts by up to 87% and 84%, respectively, when injected i.p.	Ibotenic Acid	109-118	vasoactive intestinal polypeptide	Mus musculus	69-72	
10027860-7	1999	RO-25-1553, a long-lasting cyclic VIP analog, and stearyl-norleucine-VIP, a fatty derivative of VIP, reduced ibotenate-induced white matter cysts by up to 87% and 84%, respectively, when injected i.p.	Ibotenic Acid	109-118	vasoactive intestinal polypeptide	Mus musculus	69-72	
10027860-11	1999	Furthermore, RO-25-1553 and stearyl-norleucine-VIP still induced significant neuroprotection of the developing white matter when injected systemically 8 and 12 h, respectively, after ibotenate, establishing these peptides as therapeutic agents in this murine model.	Ibotenic Acid	183-192	vasoactive intestinal polypeptide	Mus musculus	47-50	
12106022-8	1990	Thus, based on this metabotropic action, EAA can be categorized into the following classes: (i) those that potentiate the effect of VIP, such as glutamate, aspartate, kainate and ibotenate; (ii) those that inhibit the effect of VIP, such as l-homocysteate and quisqualate; and (iii) those that are ineffective, such as NMDA and d-homocysteate.	Ibotenic Acid	179-188	vasoactive intestinal polypeptide	Mus musculus	132-135	
12106022-9	1990	The effects of glutamate or ibotenate on VIP-stimulated cAMP formation were completely inhibited by l-phosphoserine and only partially by kynurenate.	Ibotenic Acid	28-37	vasoactive intestinal polypeptide	Mus musculus	41-44